Advertisement

Topics

Kensey Nash Corp. Company Profile

17:41 EST 20th November 2017 | BioPortfolio


News Articles [194 Associated News Articles listed on BioPortfolio]

Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements

Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working...   

GENFIT – The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d’Information sur la NASH, le 12 juin 2018

GENFIT — Thursday, July 13th 2017 at 5:19pm UTC GENFIT – The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d’Information sur la NASH, le 12 ju...

Boehringer Ingelheim Partners with Target PharmaSolutions to Progress NASH Research

CHAPEL HILL, N.C., Oct. 19, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Boehringer Ingelheim International GmbH has entered ...

The NASH Education Program™: Key Insights from the First US Survey Commissioned by the NASH ...

Read more...

Bristol-Myers Squibb Extends Partnership with Target PharmaSolutions for TARGET-NASH

CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic...

GENFIT ??? The NASH Education Programtm Announces The Launch Of The First International NASH Information Day On June 12, 2018: Save The Date!

  Life Sciences Jobs   ...

Boehringer, Dicerna Bang Out $201M NASH R&D Deal

The partnership will initially focus on NASH, a devastating, chronic liver disease for which there is no approved treatment option.

Gilead Shows Off Mid-Stage NASH Data

Gilead released results from a Phase II clinical trial of GS-0976 for NASH.

PubMed Articles [112 Associated PubMed Articles listed on BioPortfolio]

Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England.

There are no national studies evaluating the epidemiology of non-alcoholic steatohepatitis (NASH) in England. NASH is becoming an increasingly important health issue given the inexorable rise in obesi...

A Novel Role of Astrocyte Elevated Gene-1 (AEG-1) in Regulating Non-alcoholic Steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is the most prevalent cause of chronic liver disease in the Western world. However, an optimum therapy for NASH is yet to be established mandating more in-depth inv...

Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.

Nonalcoholic fatty liver disease (NAFLD) is a major public health concern in western societies. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is characterized by hepatic steatosi...

The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.

Non-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity and overweight. It has a broad spectrum of clinical and histological presentations, such as steatosis, inflammation (kno...

Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects.

Bile acids (BA) are signalling molecules controlling energy homeostasis which can be both toxic and protective for the liver. BA alterations have been reported in obesity, insulin resistance (IR) and ...

Clinical Trials [117 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [60 Associated Companies listed on BioPortfolio]

Kensey Nash Corp.

Kensey Nash Corporation

Kensey Nash

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occlud...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

More Information about "Kensey Nash Corp." on BioPortfolio

We have published hundreds of Kensey Nash Corp. news stories on BioPortfolio along with dozens of Kensey Nash Corp. Clinical Trials and PubMed Articles about Kensey Nash Corp. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kensey Nash Corp. Companies in our database. You can also find out about relevant Kensey Nash Corp. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record